Drop A1C Without Injections: What the Landmark CGM Trial Means for Non-Insulin Type 2 Diabetes

Picture an adult with type 2 diabetes who does not take insulin [1, 2]. Now and then, they prick a finger and read a single number [1]. That number is a single snapshot—it says nothing about the hours before or after [1].

A landmark study published on October 14, 2026, in the New England Journal of Medicine (NEJM) asked a simple question: What if that person wore a small sensor that tracked blood sugar continuously all day and all night [1]? After six months, trial participants who wore the sensor demonstrated significantly superior blood sugar control compared to those relying on conventional care [1, 2].

Why This Topic Is Trending Right Now

Three distinct factors landed simultaneously to make continuous glucose monitoring (CGM) in non-insulin-treated type 2 diabetes a major clinical topic:

• High-Impact Journal & Clinical Presentation: The results of the CONNECT trial were presented at the American Diabetes Association (ADA) Scientific Sessions ^{[3], [4]} and simultaneously published in the New England Journal of Medicine ^[1].
• Upcoming Medicare Coverage Decisions: Currently, Medicare covers CGMs primarily for individuals on insulin or with documented problematic hypoglycemia [5]. The Centers for Medicare & Medicaid Services is evaluating wider coverage, with manufacturer Dexcom expecting a regulatory update before the end of 2026 ^[5].
• Over-the-Counter (OTC) Availability: Following FDA clearance of the first over-the-counter sensor for non-insulin adults in 2024, direct-to-consumer sensors have expanded access [1, 5]. Industry data show approximately 25 million U.S. adults live with type 2 diabetes without using insulin—representing a massive population that could potentially benefit [1, 5].

First, What Is a Continuous Glucose Monitor?

A continuous glucose monitor (CGM) is a compact wearable device fitted with a microscopic sensor placed beneath the skin (typically on the back of the upper arm) [1, 2]. It checks glucose levels in the interstitial fluid every few minutes and wirelessly transmits readings to a smartphone or dedicated reader [1].

While a standard finger-stick blood test acts like a still photograph of a single moment, a CGM acts like a streaming video [1]. It reveals real-time trends, including post-meal blood sugar spikes and dips following physical activity [1].

To evaluate glycemic control, clinical trials focus on two key metrics [1, 6]:

• HbA1C (A1C): A standard blood test reflecting average blood sugar levels over the preceding 2 to 3 months [1].
• Time in Range (TIR): The percentage of time per day that glucose readings stay within a target physiological window—defined in the CONNECT trial as 70 to 180 mg/dL [1, 2].

What the Latest Research Says

How the Trial Worked

The CONNECT trial was a prospective, multicenter randomized controlled trial (RCT)—the gold standard for evaluating clinical interventions [1]. It enrolled 283 adults with type 2 diabetes who were not taking insulin across 22 primary care practices in the United States ^[1]. Participants had an average age of 60 years and an baseline A1C of 7.5% or higher (mean baseline A1C was ~8.7–8.8%) ^[1]. Approximately 40% of participants were also utilizing incretin-based medications such as GLP-1 receptor agonists [1].

Participants were randomly assigned 1:1 to either receive a prescription Dexcom G7 sensor or standard care with routine finger-stick blood glucose monitoring ^[1]. Both cohorts received basic diet and exercise education and continued their standard prescription medications over a 26-week (6-month) evaluation period ^[1].

What the Researchers Actually Found

The sensor cohort demonstrated statistically significant and clinically meaningful improvements across primary endpoints compared to routine finger-stick testing ^{[1], [2]}:

Notable secondary findings include:

• High Baseline Benefit: Participants entering the trial with severe hyperglycemia (baseline A1C > 10%) experienced a dramatic 3.1 point drop in A1C in the sensor arm—2.1 points lower than the routine care group ^[1].
• High Adherence & Device Retention: Median sensor wear time was 97%, indicating high real-world usability in primary care settings ^[1].
• Psychosocial Improvements: CGM users reported greater satisfaction with diabetes management and significantly lower diabetes-related distress ^[1].
• Subgroup Consistency: The benefits were consistent across age, sex, race, ethnicity, BMI, diabetes duration, and background medication use (including GLP-1 drugs) ^[1].

How This Fits With Earlier Research

Prior to CONNECT, a 2025 systematic review and meta-analysis of eight smaller RCTs (comprising 541 adults) found an average A1C drop of 0.4 points and a 9% improvement in time in range with CGM in non-insulin users ^[6]. The CONNECT trial confirms this direction in a much larger, real-world primary care population, demonstrating even larger treatment effects ^{[1], [6]}.

In response to emerging evidence, the American Diabetes Association updated its 2026 Standards of Care, stating that CGMs may be offered to adults with type 2 diabetes not using insulin who could benefit from improved glycemic management ^[7].

What This Means for Type 2 Diabetes and Metabolic Health

A 0.9-point net gap in A1C reduction between groups is clinically meaningful [1]. Large observational studies have long established that lower sustained A1C levels correlate with reduced risks of microvascular complications affecting the eyes, kidneys, and peripheral nerves [1].

However, clinical rigor requires noting trial boundaries: CONNECT was a 6-month trial and was not powered to directly track long-term cardiovascular or microvascular event rates [1]. Furthermore, trial summaries did not report explicit weight loss data, so CGMs cannot be definitively categorized as weight-loss tools [1]. For those managing abdominal obesity and visceral fat alongside diabetes, comprehensive lifestyle interventions remain essential.

Practical Implications & Real-World Considerations

Why does wearing a sensor improve glycemic control if the device itself delivers no medication [1]?

• Behavioral Feedback Loops: Immediate visual feedback allows patients to connect specific foods, meal timing, and physical activity directly to glucose spikes, enabling immediate lifestyle adjustments [1].
• Actionable Clinical Data: Continuous data streams give primary care clinicians clearer visibility into glycemic patterns, enabling more precise medication adjustments [1]. See our analysis on 2026 Type 2 Diabetes Guidelines and Metformin First-Line Protocols.

Cost remains a key factor [1, 5]. Prescription sensors like Dexcom G7 last approximately 10 days per unit, while OTC sensors like Dexcom Stelo last 15 days [1, 5]. Out-of-pocket costs vary based on insurance coverage and pharmacy benefit structures [1, 5].

What We Know vs. What We Don’t Know

What We Know (High-Quality Evidence)

• Strong Evidence CGMs lower A1C and increase time in range over 6 months in non-insulin type 2 diabetes adults with starting A1C ≥ 7.5% ^{[1], [2]}.
• Strong Evidence High patient wear adherence (97% median) and reduced diabetes distress accompany CGM use ^[1].
• Moderate Evidence Subgroup analysis shows consistent benefits regardless of GLP-1 drug usage, age, or BMI ^[1].

What We Don’t Know (Clinical Limitations)

• Extension Ongoing Whether A1C gains are fully sustained at 12 months (a 12-month trial extension is currently underway) ^[1].
• Unmeasured Long-term prevention rates of diabetic neuropathy, nephropathy, or retinopathy ^[1].
• Unmeasured Precise impact on body weight and severe hypoglycemia rates in this specific cohort ^[1].
• Funding Context The CONNECT trial was funded by device maker Dexcom; while trial management was led by independent university researchers, replication studies are standard practice ^[1].

Common Misconceptions Debunked

Misconception 1: “A CGM automatically lowers blood sugar on its own.”
Fact: The sensor is solely an information tool. In the trial, glycemic improvements resulted from patients and clinicians using real-time data to modify diet, exercise, and medication management [1].

Misconception 2: “Only patients taking insulin need continuous glucose tracking.”
Fact: The 2026 ADA Standards of Care and CONNECT trial data show non-insulin users with elevated A1C can achieve meaningful glycemic gains ^{[1], [7]}.

Misconception 3: “CGM sensor readings should match finger-stick values exactly.”
Fact: CGMs measure interstitial fluid glucose, which lags behind blood glucose by a few minutes. During rapid blood sugar shifts, finger-stick blood tests remain the reference check [1].

Misconception 4: “This trial proves every adult should wear a CGM sensor.”
Fact: The study specifically evaluated adults with type 2 diabetes and an A1C ≥ 7.5%. It did not study healthy adults without diabetes or individuals with well-controlled A1C levels [1].

Who Should Pay Particular Attention

This research is especially relevant if you:

• Are an adult with type 2 diabetes not currently using insulin [1].
• Have an A1C above your target goal set by your physician [1].
• Experience uncertainty regarding how specific meals or activities affect your glucose trends [1].

Precautionary Note: Contact your healthcare provider if you experience skin irritation or contact dermatitis from the sensor adhesive, or if real-time tracking causes increased anxiety [1].

Practical, Evidence-Based Recommendations

Consider discussing the following topics with your clinical care team:

1. Evaluate Fit: Review your recent A1C level to determine whether a 30-to-90-day CGM trial fits your management plan [1].
2. Establish Target Ranges: Define your personal glycemic targets and clear action steps for high or low readings [1].
3. Identify Patterns: Look for post-meal glucose spikes or post-exercise drops rather than focusing on single isolated numbers [1].
4. Maintain Essential Lifestyle Habits: Dietary quality, regular physical activity, sleep hygiene, and prescribed medications remain the core pillars of metabolic health [1]. Explore evidence on Type 2 Diabetes Remission & 5-Year Outcomes.

Metabolic Health & Dietary Support Products

In addition to blood sugar tracking, evidence-based nutrition and dietary fiber supplements play an important supportive role in glycemic control and metabolic health:

Frequently Asked Questions

Do I need a CGM if I have type 2 diabetes and don’t take insulin?

Not automatically. The CONNECT trial demonstrates that CGMs can benefit non-insulin users whose A1C remains above target, but decision-making should be individualized with your doctor based on clinical goals and insurance coverage ^[1].

Will a CGM lower my A1C on its own?

No. The sensor provides continuous data; glycemic reductions occur when patients and doctors use that data to adjust nutrition, physical activity, and medication regimens ^[1].

Will Medicare or my private insurance pay for a CGM if I don’t use insulin?

Coverage varies. Medicare currently requires insulin therapy or documented severe hypoglycemia, though policy updates are actively under consideration ^[5]. Check with your specific insurance provider.

Can I buy a CGM without a prescription?

Yes, in the United States, FDA-cleared over-the-counter sensors (such as Dexcom Stelo) are available for non-insulin users, usually paid out of pocket ^[5].

What is a good target time in range?

In the CONNECT trial, the standard target range was set at 70 to 180 mg/dL, with the sensor group averaging 62% time in range ^{[1], [2]}. Discuss your personalized target range with your care team.

Is a CGM useful for individuals without diabetes?

The CONNECT study evaluated only adults with diagnosed type 2 diabetes and elevated A1C. It does not provide evidence for CGM use in healthy populations without metabolic disease ^[1].

References & Scientific Literature

1. Oser T, Beck RW, et al. CONNECT randomized trial of continuous glucose monitoring in adults with type 2 diabetes not using insulin. New England Journal of Medicine. Published October 14, 2026. DOI: 10.1056/NEJMoa2608571. Read NEJM Full Study.
2. University of Colorado Anschutz Medical Campus. Continuous glucose monitors help type 2 diabetes patients spend five more hours a day in healthy blood sugar range. CU Anschutz News Release.
3. American Diabetes Association. Press release on the CONNECT trial, 2026 Scientific Sessions. ADA Official Press Release.
4. Cleveland Clinic Journal of Medicine. ADA 2026 coverage: CONNECT trial (Abstract 1170-OR). CCJM Summary.
5. Aronson R, Abitbol A, Bajaj HS, et al. Systematic review and meta-analysis of continuous glucose monitoring in non-insulin-treated type 2 diabetes. Diabetes, Obesity and Metabolism. 2025;27(11):6220-6242. Meta-Analysis Summary.
6. Patient Care Online. ADA publishes 2026 Standards of Care updates. ADA 2026 Standards Overview.
7. MedTech Dive. Dexcom, Abbott await Medicare coverage expansion for CGMs. MedTech Coverage Report.